Vismodegib
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB08828 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 100 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | medulloblastoma with extensive nodularity | KG + DL |
| 2 | xeroderma pigmentosum | KG + DL |
| 3 | annular epidermolytic ichthyosis | KG + DL |
| 4 | epidermolysis bullosa simplex with mottled pigmentation | KG + DL |
| 5 | prostate cancer/brain cancer susceptibility | KG + DL |
| 6 | Brenner tumor | KG + DL |
| 7 | cutaneous adenocystic carcinoma | KG + DL |
| 8 | prostate leiomyoma | KG + DL |
| 9 | skin cancer | KG + DL |
| 10 | benign neoplasm of sweat gland | KG + DL |
| 11 | fibroma of prostate | KG + DL |
| 12 | benign reproductive system neoplasm | KG + DL |
| 13 | male reproductive organ cancer | KG + DL |
| 14 | trichothiodystrophy photosensitive | KG + DL |
| 15 | eccrine carcinoma | KG + DL |
| 16 | benign prostate phyllodes tumor | KG + DL |
| 17 | obsolete cataract, microcephaly, failure to thrive, kyphoscoliosis syndrome | KG + DL |
| 18 | eccrine sweat gland neoplasm | KG + DL |
| 19 | invasive breast carcinoma | KG + DL |
| 20 | trichothiodystrophy nonphotosensitive | KG + DL |
| 21 | epidermolysis bullosa simplex with circinate migratory erythema | KG + DL |
| 22 | epidermolysis bullosa simplex with anodontia/hypodontia | KG + DL |
| 23 | KRT14-related epidermolysis bullosa simplex | KG + DL |
| 24 | sebocystomatosis | KG + DL |
| 25 | nasopharyngeal type undifferentiated carcinoma | KG + DL |
| 26 | steatocystoma multiplex-natal teeth syndrome | KG + DL |
| 27 | epidermolysis bullosa simplex due to BP230 deficiency | KG + DL |
| 28 | epidermolysis bullosa simplex due to exophilin 5 deficiency | KG + DL |
| 29 | salivary gland large cell carcinoma | KG + DL |
| 30 | kidney carcinoma in situ | KG + DL |
| 31 | gall bladder carcinoma in situ | KG + DL |
| 32 | laryngeal adenoid cystic carcinoma | KG + DL |
| 33 | sarcomatoid transitional cell carcinoma | KG + DL |
| 34 | eye carcinoma in situ | KG + DL |
| 35 | carcinoma in situ of ureter | KG + DL |
| 36 | liver carcinoma in situ | KG + DL |
| 37 | basal cell neoplasm | KG + DL |
| 38 | salivary gland epithelial myoepithelial carcinoma | KG + DL |
| 39 | Littre gland carcinoma | KG + DL |
| 40 | lipid-rich breast carcinoma | KG + DL |
| 41 | salivary gland carcinoma ex pleomorphic adenoma | KG + DL |
| 42 | carcinoma in situ of urethra | KG + DL |
| 43 | larynx carcinoma in situ | KG + DL |
| 44 | subglottis carcinoma | KG + DL |
| 45 | lung sarcomatoid carcinoma | KG + DL |
| 46 | thymic sarcomatoid carcinoma | KG + DL |
| 47 | tracheal adenoid cystic carcinoma | KG + DL |
| 48 | scrotum Paget disease | KG + DL |
| 49 | submucosal invasive colon adenocarcinoma | KG + DL |
| 50 | lacrimal gland carcinoma ex pleomorphic adenoma | KG + DL |
(Showing top 50 of 100 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.